AR and pachyonychia congenita: Numerous studies have suggested that identification of androgen receptor (AR) aberrations such as amplification, point mutations, rearrangements and splicing variants leading to reactivation of signaling are present in 50–70% of advanced PC patients and are associated with worse outcomes in mCRPC treated with ARSi [69,70,71].